Lonidamine (150 mg x 3 day orally, days 1-5) plus high dose epidoxorubicin (120 mg/m2 intravenously, day 3) was tested in 26 patients with refractory or recurrent epithelial ovarian cancer, to assess the anti-tumour activity and the toxicity of this combination of drugs. All patients were evaluable for toxicity and 24 for tumour response. Two complete responses (8.3\%) and six partial responses (25.0\%) were recorded for a total response rate of 33.3\%. 6 of 8 responding patients were pretreated with anthracyclines. Stable disease was obtained in 7 patients (29.2\%). Toxicity was acceptable; only 1 (3.8\%) patient stopped chemotherapy because of a left ventricular ejection rate reduction > 20\%. The most relevant side-effect was leucopenia (grade 3-4, 34.6\%). In conclusion, the association of lonidamine and high-dose epidoxorubicin has promising activity as second-line treatment in patients with refractory or recurrent epithelial ovarian cancer.
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer / A., Gadducci; I., Brunetti; M. P., Muttini; A., Fanucchi; F., Dargenio; P. G., Giannessi; Conte, Pierfranco. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 30A:(1994), pp. 1432-1435.
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
CONTE, Pierfranco
1994
Abstract
Lonidamine (150 mg x 3 day orally, days 1-5) plus high dose epidoxorubicin (120 mg/m2 intravenously, day 3) was tested in 26 patients with refractory or recurrent epithelial ovarian cancer, to assess the anti-tumour activity and the toxicity of this combination of drugs. All patients were evaluable for toxicity and 24 for tumour response. Two complete responses (8.3\%) and six partial responses (25.0\%) were recorded for a total response rate of 33.3\%. 6 of 8 responding patients were pretreated with anthracyclines. Stable disease was obtained in 7 patients (29.2\%). Toxicity was acceptable; only 1 (3.8\%) patient stopped chemotherapy because of a left ventricular ejection rate reduction > 20\%. The most relevant side-effect was leucopenia (grade 3-4, 34.6\%). In conclusion, the association of lonidamine and high-dose epidoxorubicin has promising activity as second-line treatment in patients with refractory or recurrent epithelial ovarian cancer.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
